Copy-number gains (e.g., ERBB2 amplification) and certain structural variants generally require higher ctF for reliable detection, and plasma-based tumor mutational burden (bTMB) can be biased downward when few tumor molecules are captured. Here, ERBB2 is linked to neoplasm.